Asset Details
Do you wish to reserve the book?
CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
Do you wish to request the book?
CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
2025
Overview
Background Single antigen (Ag)‐targeted immunotherapies for acute lymphoblastic leukemia (ALL) are highly effective; however, up to 50% of patients relapse after these treatments. Most of these relapses lack target Ag expression, suggesting targeting multiple Ags would be advantageous. Materials & Methods The multi‐Ag immune responses to ALL induced by transducing cell lines with xenoAgs green fluorescent protein and firefly luciferase was elucidated using flow cytometry, ELISA, and ELISpot assays. Results In our model, leukemia responsiveness correlates with in vivo CD4+ T cell activation and DC maturation, supporting a role for DC licensing. In contrast, tolerance is characterized by in vivo increased expression of negative immune checkpoints (IC) which may suppress rather than license DC. In vitro assays confirm the ability of CD4+ T cells from leukemia‐responsive mice to promote robust maturation of naïve bone marrow DC in the presence of non‐immunogenic leukemia antigens. Conclusion Together these findings support a CD4+ T cell‐mediated mechanism of DC licensing to promote multi‐Ag immune responses that may augment current targeted immunotherapies and avoid relapses in treated children with ALL. CD4+ T cell‐mediated mechanism of DC licensing can promote multi‐Ag immune responses that may augment current targeted immunotherapies.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
